Skip to main content
. 2017 Mar 7;8:240. doi: 10.3389/fimmu.2017.00240

Figure 7.

Figure 7

Treatment with AS101 decreases glomerular connective tissue growth factor (CTGF) and monocyte chemoattractant protein-1 (MCP-1) protein expression in crescentic glomerulonephritis and in vitro. Rats were treated as follows: daily i.p. injection with PBS with no αGBM administration (control); daily injection with PBS after αGBM injection (αGBM); daily i.p. injection with AS101 (100 μg/rat) starting 6 days after αGBM administration (AS101(+6) + αGBM); Glomerular CTGF (A) or MCP-1 (B) protein expression were evaluated on weeks 1, 2, and 3 after αGBM administration. Data are presented as mean ± SE of 5 rats/group for each time point. #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used. Glomerular mesangial cells were cultured on fibronectin-coated plates with or without various doses of AS101 and 10 μg/ml LPS for 48 h. Supernatants were collected and assayed for CTGF (C) and MCP-1 (D) content by ELISA. Results represent mean ± SE of three experiments. *p < 0.05 decrease vs. control; **p < 0.01 decrease vs. control. The one-way ANOVA was used.